In the TITAN trial, health-related quality of life did not worsen with the addition of apalutamide to ADT versus placebo for patients with metastatic castration-sensitive prostate cancer.
In mCRPC patients previously treated with docetaxel and either abiraterone or enzalutamide, third-line therapy with cabazitaxel offered longer imaging-based progression-free survival and overall survival compared with switching patients to the other antiandrogen, the CARD study found.
In a secondary analysis of NRG Oncology/RTOG 9601, some patients had no survival benefit from long-term antiandrogen treatment.
In a study, women with bladder cancer had approximately 1.5-fold higher mortality than men — but only in the short term.
In a study of radical prostatectomy patients with Gleason score 7 prostate cancer, the risk for biochemical recurrence more than doubled in the presence of tertiary pattern 5 disease.
Uniform use of computed tomography for hematuria workups marginally increases detection of urinary tract cancers while raising the risk for secondary cancers from imaging-associated radiation, researchers concluded.
In a meta-analysis, partial and radical nephrectomy were associated with similar long-term overall survival, but cancer-specific survival was better with radical nephrectomy.
Nivolumab plus ipilimumab, both checkpoint inhibitors, exhibit promising anti-tumor activity in patients with advanced renal cell carcinoma with brain metastases, researchers report.